Equities analysts expect that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report sales of $8.49 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $9.00 million and the lowest estimate coming in at $7.66 million. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 14th.

On average, analysts expect that Heron Therapeutics will report full year sales of $8.49 million for the current fiscal year, with estimates ranging from $26.69 million to $29.90 million. For the next financial year, analysts expect that the firm will post sales of $69.45 million per share, with estimates ranging from $55.00 million to $83.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million.

HRTX has been the topic of a number of recent research reports. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Northland Securities initiated coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective on the stock. Noble Financial reiterated a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Heron Therapeutics in a research note on Monday, June 26th. Finally, Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $28.50.

Heron Therapeutics (NASDAQ HRTX) opened at 15.50 on Friday. The stock’s market capitalization is $839.14 million. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85. The stock’s 50 day moving average is $15.79 and its 200 day moving average is $15.20.

Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Heron Therapeutics by 78.8% during the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after acquiring an additional 17,442 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics during the second quarter valued at approximately $78,134,000. FMR LLC lifted its position in Heron Therapeutics by 36.7% during the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after acquiring an additional 2,158,041 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Heron Therapeutics by 7.4% during the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after acquiring an additional 14,086 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Heron Therapeutics during the first quarter valued at approximately $2,002,000.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/22/heron-therapeutics-inc-hrtx-expected-to-announce-quarterly-sales-of-8-49-million.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.